Katherine Stueland - GeneDx Holdings CEO President
| WGS Stock | 78.71 6.64 9.21% |
CEO
Katherine Stueland is CEO President of GeneDx Holdings Corp
| Age | 48 |
| Address | North Tower, Stamford, CT, United States, 06902 |
| Phone | 888 729 1206 |
| Web | https://www.genedx.com |
Latest Insider Transactions
Katherine Stueland Latest Insider Activity
Tracking and analyzing the buying and selling activities of Katherine Stueland against GeneDx Holdings stock is an integral part of due diligence when investing in GeneDx Holdings. Katherine Stueland insider activity provides valuable insight into whether GeneDx Holdings is net buyers or sellers over its current business cycle. Note, GeneDx Holdings insiders must abide by specific rules, including filing SEC forms every time they buy or sell GeneDx Holdings'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Katherine Stueland over a week ago Disposition of tradable shares by Katherine Stueland of GeneDx Holdings at 74.3389 subject to Rule 16b-3 | ||
Katherine Stueland over three weeks ago Acquisition by Katherine Stueland of 18750 shares of GeneDx Holdings subject to Rule 16b-3 | ||
Katherine Stueland over two months ago Disposition of 6546 shares by Katherine Stueland of GeneDx Holdings subject to Rule 16b-3 | ||
Katherine Stueland over two months ago Disposition of 6546 shares by Katherine Stueland of GeneDx Holdings subject to Rule 16b-3 |
GeneDx Holdings Management Efficiency
The company has Return on Asset of (0.0827) % which means that on every $100 spent on assets, it lost $0.0827. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.364) %, meaning that it generated no profit with money invested by stockholders. GeneDx Holdings' management efficiency ratios could be used to measure how well GeneDx Holdings manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.61 in 2024. Return On Capital Employed is likely to drop to -0.41 in 2024. At this time, GeneDx Holdings' Net Tangible Assets are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 13.5 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 197.4 M in 2024.Similar Executives
| Found 2 records | CEO Age | ||
| Jacob Cohen | Mangoceuticals, Common Stock | 45 | |
| Brent Ness | Aclarion | 57 | |
Management Performance
| Return On Equity | -0.36 | ||||
| Return On Asset | -0.0827 |
GeneDx Holdings Corp Leadership Team
Elected by the shareholders, the GeneDx Holdings' board of directors comprises two types of representatives: GeneDx Holdings inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GeneDx. The board's role is to monitor GeneDx Holdings' management team and ensure that shareholders' interests are well served. GeneDx Holdings' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GeneDx Holdings' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel JD, Secretary | ||
| Britt Johnson, Head Affairs | ||
| Katherine Stueland, CEO President | ||
| Jami Biliboaca, Head Strategy | ||
| Eric Olivares, Chief Officer | ||
| Tricia Truehart, Head Relations | ||
| MBA JD, General Counsel | ||
| FACMG MD, Chief Officer | ||
| Sabrina Dunbar, Chief Staff | ||
| Jerry Conway, Senior Access | ||
| Kevin Feeley, Chief Officer | ||
| Paul MD, Chief Officer | ||
| Melanie Duquette, Chief Officer | ||
| Jennifer Brendel, Chief Affairs | ||
| Feras Hantash, Senior Oncology | ||
| Kevin CPA, Chief Officer | ||
| Jason Ryan, Executive Board | ||
| Karen Ponchner, Senior Operations |
GeneDx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GeneDx Holdings a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.36 | ||||
| Return On Asset | -0.0827 | ||||
| Profit Margin | (0.31) % | ||||
| Operating Margin | (0.10) % | ||||
| Current Valuation | 2.16 B | ||||
| Shares Outstanding | 27.47 M | ||||
| Shares Owned By Insiders | 18.20 % | ||||
| Shares Owned By Institutions | 70.24 % | ||||
| Number Of Shares Shorted | 2.6 M | ||||
| Price To Book | 10.57 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for GeneDx Stock Analysis
When running GeneDx Holdings' price analysis, check to measure GeneDx Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneDx Holdings is operating at the current time. Most of GeneDx Holdings' value examination focuses on studying past and present price action to predict the probability of GeneDx Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneDx Holdings' price. Additionally, you may evaluate how the addition of GeneDx Holdings to your portfolios can decrease your overall portfolio volatility.